ACADIA Pharmaceuticals Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Catherine Owen Adams
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 1.3yrs |
| Board average tenure | 9yrs |
Recent management updates
Recent updates
Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET
Nov 27Acadia Pharmaceuticals: Proving The Naysayers Wrong
Nov 11ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Nov 08
Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again
Aug 26The Strong Earnings Posted By ACADIA Pharmaceuticals (NASDAQ:ACAD) Are A Good Indication Of The Strength Of The Business
Aug 14ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 09ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Aug 01Shareholders Will Probably Hold Off On Increasing ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation For The Time Being
May 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Apr 24We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Mar 27Acadia Pharmaceuticals: Post Pimavanserin Study Setback Selloff May Continue
Mar 12ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Just Released Its Full-Year Earnings: Here's What Analysts Think
Mar 01Acadia Pharmaceuticals: New Daybue Drug Already Showing Signs Of Slowing
Feb 29Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families
Jan 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Share Price Boosted 35% But Its Business Prospects Need A Lift Too
Jan 03We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Dec 04Insufficient Growth At ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Hampers Share Price
May 22Acadia Pharmaceuticals: Nuplazid's (Pimavanserin) Last Hurrah
Oct 19FDA accepts Acadia's new drug application for Rett syndrome treatment trofinetide
Sep 12Acadia: Powerful Unfolding Catalysts
Aug 03CEO
Catherine Owen Adams (54 yo)
less than a year
Tenure
Ms. Catherine E. Owen Adams is CEO & Director of ACADIA Pharmaceuticals Inc. from September 23, 2024. Ms. Owen Adams served as Director of OptiNose US, Inc. since July 2020 until September 24, 2024. She se...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive VP & CFO | 3.3yrs | US$2.59m | 0.032% $ 927.9k | |
| Consultant | less than a year | US$7.59m | 0.11% $ 3.2m | |
| Non-Executive Employee | less than a year | US$2.62m | 0.037% $ 1.1m | |
| CEO & Director | less than a year | no data | no data | |
| VP, Chief Accounting Officer & Corporate Controller | 4.3yrs | no data | 0.012% $ 345.9k | |
| Executive VP and Head of Research & Development | less than a year | no data | no data | |
| Senior Vice President of Technical Development | 2.1yrs | no data | no data | |
| Senior Vice President of Investor Relations & Corporate Communications | 1.3yrs | no data | no data | |
| Executive VP | less than a year | no data | no data | |
| Senior VP & Chief People Officer | 2.9yrs | no data | no data | |
| Senior Vice President of New Product Planning & Strategy | no data | no data | no data | |
| SVP, Global Head of Medical Affairs & Chief Medical Officer | 5.1yrs | no data | no data |
1.3yrs
Average Tenure
54yo
Average Age
Experienced Management: ACAD's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | no data | no data | |
| Independent Director | 16.6yrs | US$392.75k | 0.012% $ 350.8k | |
| Independent Director | 9yrs | US$377.75k | 0.062% $ 1.8m | |
| Member of the Scientific and Clinical Advisory Board | no data | no data | no data | |
| Independent Director | 9.1yrs | US$387.75k | 0.015% $ 446.7k | |
| Independent Director | 9.8yrs | US$387.75k | 0.021% $ 603.4k | |
| Member of the Scientific and Clinical Advisory Board | no data | no data | no data | |
| Member of the Scientific and Clinical Advisory Board | no data | no data | no data | |
| Member of the Scientific and Clinical Advisory Board | no data | no data | no data | |
| Independent Director | 8.9yrs | US$387.75k | 0.015% $ 429.3k | |
| Independent Chairman of the Board | 11.9yrs | US$432.75k | 0.062% $ 1.8m | |
| Independent Director | 4.3yrs | US$377.75k | 0.014% $ 391.9k |
9.0yrs
Average Tenure
66yo
Average Age
Experienced Board: ACAD's board of directors are considered experienced (9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 05:36 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ACADIA Pharmaceuticals Inc. is covered by 39 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert LeBoyer | Aegis Capital Corporation |
| Joel Beatty | Baird |
| Ishan Majumdar | Baptista Research |